EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Chemically Programmable Antibody-Drug Conjugates: Strategies from Targeting Programmability to Payload Activation

Boyu Shi

International Journal of Biology and Life Sciences · 15.11.2026 · 17 (2) · 228-238

DOI: 10.54097/k2468v26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biology and Life Sciences, online erschienen am 15.11.2026. Verfasst von Boyu Shi. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) are now highly effective anticancer drugs, but their molecular functions are relatively fixed at the time of production and cannot adapt to changes in the tumor microenvironment. Chemical programmability refers to the ability to modify a predefined antibody platform after scaffold construction by exchanging, activating, or reorganizing functional modules, providing modularity and control over various functional levels in ADC design through a versatile antibody platform that can be chemically altered in terms of targeting and effector functions. Hardware-level programmability refers to the engineering of universal antibody scaffolds and conjugation sites; software-level programmability refers to exchangeable targeting ligands, payloads and release mechanisms that define therapeutic functions. The five functional levels of chemically programmable strategies are: targeting programmability, assembly programmability, target-engagement programmability, conjugation programmability, and payload-activation programmability. We trace the conceptual origins to chemically programmed antibodies using catalytic antibody 38C2 and examine the core chemical toolbox, including inverse electron-demand Diels-Alder click chemistry, click-to-release technology, sulfur (VI) fluoride exchange chemistry, and non-canonical amino acid-based conjugation. These tools have been applied in four ways: in vivo click-driven assembly, small-molecule reprogramming, antibody fragment platforms and bispecific ADCs. Key challenges are discussed alongside future directions such as integrated multi-level programmable design.

Zitieren

APA

Shi, B. (2026). Chemically Programmable Antibody-Drug Conjugates: Strategies from Targeting Programmability to Payload Activation. International Journal of Biology and Life Sciences, 17(2), 228-238. https://doi.org/10.54097/k2468v26

Vancouver

Shi B. Chemically Programmable Antibody-Drug Conjugates: Strategies from Targeting Programmability to Payload Activation. International Journal of Biology and Life Sciences. 2026;17(2):228-238. doi:10.54097/k2468v26

BibTeX
@article{Shi2026,
  author = {Shi, Boyu},
  title = {Chemically Programmable Antibody-Drug Conjugates: Strategies from Targeting Programmability to Payload Activation},
  journal = {International Journal of Biology and Life Sciences},
  year = {2026},
  volume = {17},
  number = {2},
  pages = {228--238},
  doi = {10.54097/k2468v26}
}
Kostenlos starten →